compounded semaglutide crackdown news today Demand Rising for 'Bootlegged' Weight-Loss Drug The FDA is cracking down

Retatrutide is an investigational peptide drug currently under clinical development by Eli Lilly

Because theyre also rich in the antioxidant quercetin, another compound proven to increase GLP-1 secretion

Finally, when compared with placebo, SGLT-2 inhibitors are associated with a robust reduction of hospitalization for HHF and renal outcome, and a moderate reduction of CV and total death, and MACE [13]

This often translates to fewer energy crashes and reduced cravings

Oral semaglutide 25 mg (Wegovy pill) , FDA-approved December 22, 2025, is the first oral GLP-1 approved for chronic weight management

Later that same year the orforglipron structure (Kawai et al) showed the now-recognised Trp33 ECL1 anchor that underlies the human-receptor selectivity of the modern small-molecule series